Healthcare Royalty, Inc. HCRX 深 滬
等待開盤 07-18 09:30:00 美东时间
0.00
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 總市值 0
- 52周最高 0.00
- 市盈率 靜 0.00
- 換手率 0.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 2.15亿
- 歷史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 0.00
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ADC Therapeutics Makes Grant to New Employee Under Inducement Plan
LAUSANNE, Switzerland, July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
07-02 04:05
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
06-03 04:05
REGENXBIO announces royalty monetization agreement for up to $250M
REGENXBIO (NASDAQ:RGNX) announced on Monday the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250M with Healthcare Royalty (HCRx). This agreement monetizes select antic...
05-20 04:14
REGENXBIO Announces Closure Of Non-Dilutive, Limited Recourse Royalty Bond Agreement Of Up To $250M With Healthcare Royalty
$150 million secured at closing extends cash runway into early 2027REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) and milestones from
05-20 04:08
ADC Therapeutics to Present at Upcoming Investor Conferences
LAUSANNE, Switzerland, May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
05-15 19:15
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Nov. 1, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
2024-11-02 04:05
快讯 | HealthCare Royalty和Blue Owl宣布与tg therapeutics进行2.5亿美元的债务融资
Healthcare Royalty and Blue Owl Announce $250M Debt Financing With TG Therapeut...
2024-08-06 21:02
TG Therapeutics jumps after strong Q2 beat and guidance raise
TG Therapeutics (NASDAQ:TGTX) shares rose ~16% in the premarket on Wednesday after the biotech well exceeded expectations with its Q2 2024 financials and once again raised its full-year sales outlook ...
2024-08-06 20:37
快讯 | opko健康和医疗专利权达成2.5亿美元的债券购买协议，由Ngenla的利润份额支付担保
OPKO Health and Healthcare Royalty Enter Into $250 Million Note Purchase Agreem...
2024-07-18 04:14
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023 Total Revenue Guidance of $145 M...
2023-08-02 19:30
